Since the first GLP-1 RA was successfully approved by the US Food and Drug Administration (FDA) in 2005, following intensive studies and the gradual accumulation of evidence, the status of this kind of agent in the treatment of T2D has been continuously improving. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.